TRexBio prices IPO at $14 per share on Nasdaq

TRex Bio, Inc., a clinical-stage biotechnology firm, priced its IPO at $14 per share on the Nasdaq stock exchange, according to a press release. The company aimed to raise around $116.7 million in gross proceeds, after accounting for fees and expenses. All 8.33 million shares were offered by TRexBio itself. The stock was slated to commence trading on the Nasdaq Global Select Market on October 9, 2026, under the TRXB ticker symbol.

The offering was expected to conclude on October 13, 2026, subject to standard closing conditions. TRexBio had also given underwriters the option to purchase an additional 1.25 million shares within 30 days at the initial price, less fees and commissions. Renowned financial institutions J.P. Morgan, Evercore ISI, Cantor, and Stifel served as lead book-running managers, while Wedbush PacGrow and Stifel acted as secondary book-running managers.

The company's primary focus is on tissue regulatory T-cell biology to develop therapies for autoimmune and inflammatory diseases. TRexBio's corporate headquarters are located in South San Francisco, California.